Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus PT from Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC) has been assigned a consensus rating of “Buy” from the six research firms that are covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several equities research analysts recently weighed in on IPSC shares. Chardan Capital reduced their price target on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Guggenheim reaffirmed a “buy” rating on shares of Century Therapeutics in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a research note on Wednesday. Finally, Piper Sandler decreased their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research note on Monday, December 30th.

Century Therapeutics Price Performance

NASDAQ:IPSC opened at $0.90 on Wednesday. The stock’s fifty day moving average price is $1.17 and its two-hundred day moving average price is $1.55. The company has a market cap of $76.53 million, a P/E ratio of -0.49 and a beta of 1.76. Century Therapeutics has a 1 year low of $0.86 and a 1 year high of $5.51.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. The firm had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.47 million. During the same quarter in the previous year, the business earned ($0.55) earnings per share. On average, analysts expect that Century Therapeutics will post -1.63 earnings per share for the current fiscal year.

Institutional Trading of Century Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp grew its position in shares of Century Therapeutics by 110.1% during the second quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock valued at $380,000 after purchasing an additional 78,088 shares in the last quarter. Rhumbline Advisers boosted its stake in Century Therapeutics by 56.0% during the second quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock valued at $134,000 after buying an additional 18,828 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Century Therapeutics by 141.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock valued at $192,000 after buying an additional 44,155 shares in the last quarter. Renaissance Technologies LLC increased its stake in Century Therapeutics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after acquiring an additional 9,500 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Century Therapeutics during the 3rd quarter worth approximately $27,000. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.